You just read:

Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

News provided by

Lycera Corp.

Jan 04, 2017, 08:00 ET